Navigating the Biotech Fault Line

This chapter examines the challenging landscape of the biotechnology market, highlighting investor pessimism and the stagnant performance of biotech stocks compared to major indices. The discussion focuses on the complexities of selecting individual stocks to navigate the sector's difficulties, emphasizing the phenomenon of 'zombie' biotech companies and the implications of their continuing existence. Ultimately, the talk raises questions about accountability, the viability of investments, and the harsh realities of competing in a saturated market.